PERJETA (Roche Products Pty Ltd)
Product name
PERJETA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
189 working days (255)
Active ingredients
pertuzumab
Registration type
EOI
Indication
PERJETA (injection) is now also indicated in combination with trastuzumab and chemotherapy for:
- the neoadjuvant treatment of patients with HER2-positive inflammatory or locally advanced, or early stage (either > 2 cm in diameter or node positive) breast cancer as part of a complete treatment regimen for early breast cancer
- the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.